期刊文献+

软组织肉瘤中C-KIT,PDGFRα基因突变的检测结果分析 被引量:1

Detection of C-KIT and PDGFRα mutation in non-GIST soft tissue sarcoma
下载PDF
导出
摘要 目的讨论软组织肉瘤(STS)中C-KIT,PDGFRα基因的突变情况。方法直接测序分析32例石蜡STS组织中C-KIT的突变(9,11,17外显子)和PDGFRα(12,18外显子)的突变情况。以10例胃腺癌作为对照。结果 C-KIT基因的突变率为37.5%(12/32),突变位点主要在第11外显子。PDGFRα基因未发现有活性的突变,但其中16例在12外显子第567位密码子(P567P)、4例在18外显子第824位密码子(V824V)发现同义突变。结论约三分之一的STS发生C-KIT突变,C-KIT可能是酪氨酸激酶抑制剂(TKI)在STS中一个潜在的治疗靶点。 Objective To investigate the mutation status of C-KIT and PDGFR~ in 32 Chinese clinical sam- ples with soft tissue sarcoma (STS). Methods Gcnomic DNA was isolated from 32 cases of para^n-embedded STS and presence of C-KIT (exon 9, 1 I, 17) mutation and PDGFRct (exon 12, 18) mutation were analyzed by direct se- quencing. 10 cases of gastric adenocarcinoma were used as control. Results The mutation rate for C-KIT was 37.5% (12/32). Among them, 7 in 12 examined cases had C-KIT mutations in exon 11. No activating PDGFRct mutations were found, but two silent mutations were observed, base substitution in exon 12 (CCA〉CCG) at codon 567 (P567P) in 16 cases and in exon 18 (GTC〉GTT) at codon 824 (V824V) in 4 cases. Condusion C-KIT mutations occur in ap- proximately one-third of cases of STS and may be a potential therapeutic target for STS.
出处 《海南医学》 CAS 2013年第23期3439-3442,共4页 Hainan Medical Journal
关键词 C-KIT PDGFRΑ 直接测序 软组织肉瘤 C-KIT PDGFRct Direct sequencing Soft tissue sarcoma
  • 相关文献

参考文献23

  • 1Kiesel H,Müller AM,Schmitt-GraeffA. Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations[J].{H}CANCER BIOLOGY & THERAPY,2009,(04):319-321.
  • 2Ma HB,Xu X,Liu WP. Successful treatment of mast cell sarcoma of the uterus with imatinib[J].{H}International Journal of Hematology,2011,(05):491-494.
  • 3Sanmartín O,Llombart B,L6pez-Guerrero JA. Dermatofibrosarcoma Protuberans[J].{H}Actas Dermo-sifiliograficas,2007,(02):77-87.
  • 4George S,Merriam P,Maki RG. Multicenter phase Ⅱ trial of sunitinib in the treatment ofnongastrointestinal stromal tumor sarcomas[J].{H}Journal of Clinical Oncology,2009,(19):3154-3160.
  • 5Stacchiotti S,Negri T,Zaffaroni N. Sunitinib in advanced alveolar soft part sarcoma:evidence of a direct antitumor effect[J].{H}ANNALS OF ONCOLOGY,2011,(07):1682-1690.
  • 6Cheng L,Roth LM,Zhang S. KIT gene mutation and amplification in dysgerminoma of the ovary[J].{H}CANCER,2011,(10):2096-2103.
  • 7Coffey J,Linger R,Pugh J. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease:report of 220 tumors and review of literature[J].{H}Genes Chromosomes & Cancer,2008,(01):34-42.
  • 8Georgin-Lavialle S,Lhermitte L,Suarez F. Mast cell leukemia:identification of a new c-kit mutation,dup(501-502),and response to imatinib,a c-kit tyrosine kinase inhibitor[J].{H}European Journal of haematology,2012,(01):47-52.
  • 9Riedel RF. Targeted agents for sarcoma:is individualized therapy possible in such a diverse tumor type[J].{H}Seminars in Oncology,2011,(Suppl 3):S30-S42.
  • 10Heinrich MC,Owzar K,Corless CL. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase Ⅲ trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor:CALGB150105 Study by Cancer and Leukemia Group B and Southwest.Oncology Group[J].{H}Journal of Clinical Oncology,2008,(33):5360-5367.

同被引文献15

  • 1Davies L, Welch HG. Increasing incidence of thyroid cancer in the U- nited States[J].JAMA, 2006,295(18):2164 - 2167.
  • 2Caronia LM, Phay JE, Shah MH,et al. Role of BRAF in thyroid oncogen- esis[J].Clin Cancer Res, 2011,17(24):7511-7517.
  • 3Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in pap- illary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004,45(5):818 - 821.
  • 4DeLellis RA,LLoyd R,Heitz PU.WHO classification of tumors,pathology and genetics-tumors of endocrine organs[J]. IARC Press,Lyan,2004.
  • 5Cantwell ER, O'Leary J], Sheils OM, et al. BRAFV6OOE: implications for carcinogenesis and molecular therapy[J].Mol Cancer Ther,2011,10(3): 385-394.
  • 6Sapio M R,Posca D,Troncone G,et al.Detection of BRAF mutation in thyroid papillm'y carcinoma by mutant allele-specific PCR amplification (MASA)[J].EurJ Endoerinol, 2006,154(2):341-348.
  • 7Fukushima T, Takenoshita S.Roles of RAS and BRAF mutations in thy- roid carcinogenesis[J]. Fukushima J Med Sei, 2005,51(2):67-75.
  • 8Hwang J, Shin JH, Hon BK, et at. Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction[J]. AJR Am J Roentgenol, 2010, 194(5): W425 - 430.
  • 9Nikiforov YE, Nikiforova MN .Molecular genetics and diagnosis of thy- roid cancer[J]. Nat Rcv Endocrinol,2011, 7(10): 569-580.
  • 10Zhang B, Liu S, Zhang Z, et al.Analysis of BRAF (V60OE) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies[J]. Diagn Pathol, 2014(9):45.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部